Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron Variant
David Niklas Springer, Thomas Perkmann, Claudia Jani, Patrick Mucher, Katja Prüger, Rodrig Marculescu, Elisabeth Reuberger, Jeremy V. Camp, Marianne Graninger, Christian Borsodi, Josef Deutsch, Oliver Lammel, Stephan W. Aberle, Elisabeth Puchhammer‐Stöckl, Helmuth Haslacher, Eva Höltl, Judith H. Aberle, Karin Stiasny, Lukas Weseslindtner
Abstract
This study demonstrates that the antigenic changes of the SARS-CoV-2 Omicron variant affect test results from commercial Spike- and RBD-specific antibody assays, significantly diminishing their sensitivities and diagnostic abilities to assess neutralizing antibodies.
Topics & Concepts
AntibodyVirologyAntigenTiterNeutralizationNeutralizing antibodyBiologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ImmunologyCoronavirus disease 2019 (COVID-19)MedicineDiseaseInfectious disease (medical specialty)PathologySARS-CoV-2 and COVID-19 ResearchSARS-CoV-2 detection and testingVirus-based gene therapy research